论文部分内容阅读
奈韦拉平(NVP)是第一代非核苷类逆转录酶抑制药,为治疗艾滋病和预防HIV-1母婴传播的一线药物。其溶解性差,生物利用度低。随着新剂型的开发,固体分散、自乳化、微粒、聚合物胶束、缓释片、胃漂浮微球等技术的应用可提高NVP的生物利用度,减少不良反应。本文通过文献检索对国内外NVP新剂型的研究进展进行了综述,为NVP新剂型的开发提供依据。
Nevirapine (NVP) is the first generation of non-nucleoside reverse transcriptase inhibitors, the first-line drug for the treatment of AIDS and the prevention of mother-to-child transmission of HIV-1. Its poor solubility, low bioavailability. With the development of new dosage forms, the application of technologies such as solid dispersion, self-emulsification, microparticles, polymer micelles, sustained release tablets and gastric floating microspheres can improve the bioavailability of NVP and reduce adverse reactions. This article reviews the progress of new NVP formulations both at home and abroad through literature search, and provides the basis for the development of new NVP formulations.